TP53 and sarcoma: However, the development of specific molecular-targeted drugs for LMS with a complex karyotype has not progressed, as sarcoma is a product of genomic instability due to genetic alterations, such as those in tumor protein p53 gene (TP53) and retinoblastoma gene (RB).